← All trials
NCT06225336
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2022
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Jan 25, 2024
- Last posted
- Jan 29, 2024
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Auregen Biotherapeutics, SALead sponsor
- Chris O'Brien LifehouseOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.